| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
University of Cincinnati Medical Center, Cincinnati, Ohio 45267-0595 [S. J., E. K., M. M., C. D. U.], and Veterans Affairs Medical Center, Seattle, Washington 98108 [R. H. B.]
Vasoactive intestinal peptide (VIP) appears to be responsible for atropine-resistant, neurally mediated pancreatic ductal bicarbonate secretion and plays a role in both stimulation and inhibition of neoplastic growth in other organs. cDNAs encoding high affinity VIP-1 and VIP-2 receptors have been cloned, and these receptors may be differentiated based on the ability of VIP-1, but not VIP-2, receptors to couple to adenylyl cyclase in response to stimulation with micromolar concentrations of secretin. Recent data from our laboratory suggest expression of a low affinity secretin receptor in seven cell lines derived from human ductal pancreatic adenocarcinomas. In combination with the recent use of 123I-labeled VIP to successfully image pancreatic adenocarcinomas in humans and the high affinity binding of both VIP and pituitary adenylate cyclase-activating peptides to sections from human pancreatic tumors, these findings suggest that VIP-1 receptors may be expressed on the majority of neoplastic pancreatic duct epithelial cells in vivo. To initially test the hypothesis that expression of VIP-1 receptors plays an important role in the pathophysiology of human ductal pancreatic adenocarcinomas, we used reverse transcription-PCR with Southern blot hybridization to confirm expression of VIP-1 and VIP-2 receptor mRNA in the vast majority of 28 human ductal pancreatic adenocarcinomas. Based on the cellular heterogeneity of these tumors, we also assessed VIP receptor subtype expression in seven well-characterized, secretin-responsive cell lines derived from human ductal pancreatic adenocarcinomas. Only VIP-1 receptor mRNA was detected in all seven secretin-responsive cell lines. A half-maximal increase in intracellular cyclic AMP was obtained with 0.5–5 nM VIP in each of these cell lines, consistent with expression of high affinity VIP receptors. The ability of 1 µM, but not 1 nM, secretin to stimulate intracellular cyclic AMP generation in these cells was consistent with VIP-1 receptor expression. Interestingly, 100 pM, but not 1 µM, VIP stimulated significant growth of VIP-1 receptor-bearing Capan-2 cells both in the absence and presence of serum. Because VIP-1 receptors appear to be expressed in the majority of neoplastic pancreatic duct cell lines and VIP stimulates growth of VIP-1 receptor-bearing Capan-2 cells in vitro, this peptide may well play an important role in the pathophysiology of tumors expressing these receptors in vivo.
1 This work was supported by the Division of Digestive Diseases and Department of Internal Medicine, University of Cincinnati College of Medicine, Institutional Grant IRG-189 from the American Cancer Society, as well as an American Cancer Society Ohio Division, Inc., Ohio Division Supported Research Grant.
2 To whom requests for reprints should be addressed, at Division of Digestive Diseases, University of Cincinnati College of Medicine, Medical Sciences Building (ML 0595), 231 Bethesda Avenue, Cincinnati, Ohio 45267-0595. Phone: (513) 558-5244; Fax: (513) 558-1744.
Received 8/21/96. Accepted 2/24/97.
This article has been cited by other articles:
|
|
 |
|
  S. Schulz, C. Rocken, C. Mawrin, W. Weise, V. Hollt, and S. Schulz Immunocytochemical Identification of VPAC1, VPAC2, and PAC1 Receptors in Normal and Neoplastic Human Tissues with Subtype-Specific Antibodies Clin. Cancer Res., December 15, 2004; 10(24): 8235 - 8242. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C. Reubi Peptide Receptors as Molecular Targets for Cancer Diagnosis and Therapy Endocr. Rev., August 1, 2003; 24(4): 389 - 427. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Igarashi, T. Ito, T. K. Pradhan, S. A. Mantey, W. Hou, D. H. Coy, and R. T. Jensen Elucidation of the Vasoactive Intestinal Peptide Pharmacophore for VPAC2 Receptors in Human and Rat and Comparison to the Pharmacophore for VPAC1 Receptors J. Pharmacol. Exp. Ther., November 1, 2002; 303(2): 445 - 460. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W.-Q. Ding, Z.-J. Cheng, J. McElhiney, S. M. Kuntz, and L. J. Miller Silencing of Secretin Receptor Function by Dimerization with a Misspliced Variant Secretin Receptor in Ductal Pancreatic Adenocarcinoma Cancer Res., September 15, 2002; 62(18): 5223 - 5229. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Igarashi, T. Ito, W. Hou, S. A. Mantey, T. K. Pradhan, C. D. Ulrich II, S. J. Hocart, D. H. Coy, and R. T. Jensen Elucidation of Vasoactive Intestinal Peptide Pharmacophore for VPAC1 Receptors in Human, Rat, and Guinea Pig J. Pharmacol. Exp. Ther., April 1, 2002; 301(1): 37 - 50. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C. REUBI In Vitro Evaluation of VIP/PACAP Receptors in Healthy and Diseased Human Tissues: Clinical Implications Ann. N.Y. Acad. Sci., December 1, 2000; 921(1): 1 - 25. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. ZSEMBERY, M. STRAZZABOSCO, and J. GRAF Ca2+-activated Cl- channels can substitute for CFTR in stimulation of pancreatic duct bicarbonate secretion FASEB J, November 1, 2000; 14(14): 2345 - 2356. [Abstract] [Full Text]
|
|
|
|
 |
|
 Z. Rekasi, J. L. Varga, A. V. Schally, G. Halmos, P. Armatis, K. Groot, and T. Czompoly Antagonists of Growth Hormone-Releasing Hormone and Vasoactive Intestinal Peptide Inhibit Tumor Proliferation by Different Mechanisms: Evidence from in Vitro Studies on Human Prostatic and Pancreatic Cancers Endocrinology, June 1, 2000; 141(6): 2120 - 2128. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. C. Reubi, U. Laderach, B. Waser, J.-O. Gebbers, P. Robberecht, and J. A. Laissue Vasoactive Intestinal Peptide/Pituitary Adenylate Cyclase-activating Peptide Receptor Subtypes in Human Tumors and Their Tissues of Origin1 Cancer Res., June 1, 2000; 60(11): 3105 - 3112. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Vaudry, B. J. Gonzalez, M. Basille, L. Yon, A. Fournier, and H. Vaudry Pituitary Adenylate Cyclase-Activating Polypeptide and Its Receptors: From Structure to Functions Pharmacol. Rev., June 1, 2000; 52(2): 269 - 324. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. D. Kineman Antitumorigenic actions of growth hormone-releasing hormone antagonists PNAS, January 18, 2000; 97(2): 532 - 534. [Full Text] [PDF]
|
|
|
|
 |
|
 T. Ito, W. Hou, T. Katsuno, H. Igarashi, T. K. Pradhan, S. A. Mantey, D. H. Coy, and R. T. Jensen Rat and guinea pig pancreatic acini possess both VIP1 and VIP2 receptors, which mediate enzyme secretion Am J Physiol Gastrointest Liver Physiol, January 1, 2000; 278(1): G64 - G74. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
